Atea reports Q2 2026 results, cites C-BEYOND Phase 3 win in hepatitis CAug 12Quarterly updateAtea Pharmaceuticals, Inc.
Atea registers Phase 1 first-in-human trial of AT-587 for hepatitis EJul 27Trial updateAT-587Atea Pharmaceuticals, Inc.
Sign inSign in